Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy | Synapse
January 9, 2015Open Access
Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Pegfilgrastim is safe and significantly reduces the incidence of FN in breast cancer patients.